Navigation Links
Mimedx Scientific Study Is Electronically Published in The International Wound Journal
Date:8/1/2013

MARIETTA, Ga., Aug. 1, 2013 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "Biological Properties of Dehydrated Human Amnion/Chorion Grafts: Implications for Chronic Wound Healing" has been electronically published in the International Wound Journal.  The electronic publication of the study is available at http://mimedx.com/images/pdf/Koob_IWJ_Scientific_Article_12140.pdf. The hard copy is scheduled to be published in the December 2013 edition of the International Wound Journal.

MiMedx's proprietary PURION® processed dehydrated human amnion/chorion tissue allografts (dHACM), specifically, the MiMedx EpiFix® allograft, was the subject of the study. EpiFix® was evaluated for the presence of growth factors, interleukins (ILs) and tissue inhibitors of enzymes that degrade the extracellular matrix, or metalloproteinases. Both in vitro and in vivo experiments were conducted, and it was clearly established that:

  • PURION® processed dHACM retains biologically active growth factors and regulatory factors that are at least partially responsible for its clinical effectiveness in wound healing;
  • dHACM contains one or more soluble factors that stimulate mesenchymal stem cell migration and recruitment; and
  • dHACM is a multifaceted tissue graft that has the potential to positively affect at least four distinct physiological processes:  cell proliferation, inflammation, metalloproteinase activity, and recruitment of stem cells – all of which are integral to regenerative wound healing and soft tissue repair.

"As we state
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MiMedx Announces Record Second Quarter Results
2. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
3. MiMedx To Exceed High End Of Second Quarter Guidance
4. MiMedx to Ring NASDAQ Stock Market Opening Bell
5. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
6. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
7. MiMedx Announces Record First Quarter 2013 Results
8. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
9. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
10. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
11. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 15, 2014 METTLER TOLEDO is ... tool, ParticleView V19 with PVM technology , ... particle vision and measurement tool continuously captures high-resolution ... ParticleView V19 then automatically prepares a report pairing ... size and concentration changes. This compelling blend of ...
(Date:12/15/2014)... 2014  Ascendis Pharma A/S, a biotechnology company ... significant unmet medical needs, today announced positive six-month ... study to evaluate once-weekly TransCon Growth Hormone in ... interim analysis consists of 25 patients, representing approximately ... study, completing all six months of treatment. ...
(Date:12/13/2014)... December 12, 2014 Trend lines for ... overall global economic growth, Eugene Arthurs, CEO of ... said in a featured talk at OPTIC (Optics and ... the National Chung Hsing University in Taichung. , As ... into future energy supplies and soon to hit US$50 ...
(Date:12/13/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/6p4j9m/glucose_sensors ) ... Sensors: the Next Generation" report to their ... The convergence of small-scale electronics and ... a better future to millions of diabetes patients ... levels accurately and reliably have the capability to ...
Breaking Biology Technology:New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3
... disorders, DEERFIELD, Ill., Oct. 16 Baxter ... has signed an agreement with,Kaketsuken, the Chemo-Sero-Therapeutic Research ... to develop, manufacture and market,the recombinant protein ADAMTS13. ... a naturally occurring enzyme that plays a,critical role ...
... ... Renowned Investment Banker and Biotechnology Company Start-up Leader ... Stelios Papadopoulos, PhD Provides Keynote Address, BOSTON, Oct. ... Investor Conference, New,England,s largest biotechnology investor forum, will explore ...
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... presentations at the AACR-NCI-EORTC,International Conference on Molecular Targets ... They will highlight drug discovery,efforts focused on significant ... like kinase 1 (PLK1) and Janus tyrosine kinase,2 ...
Cached Biology Technology:Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio 2Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio 3Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio 42007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies 22007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies 3Rigel to Present Research Programs at Scientific Conferences 2Rigel to Present Research Programs at Scientific Conferences 3
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... MADISON Using the meticulous phenological records of two iconic ... demonstrated that native plants in the eastern United States are ... a warming climate. The new study is important because ... ecological change in response to a warming world. In addition, ...
... The latest study by Professor Bob Elwood and Barry ... the reactions of common shore crabs to small electrical ... research has been published in the Journal of ... prawns and hermit crabs respond in a way consistent ...
... a troubling consequence of their own success. They created drugs ... However, those same drugs will eventually cause the constantly mutating ... With a new $3.4 million grant from the National ... team of researchers who want to stay a step ahead ...
Cached Biology News:In the Eastern US, spring flowers keep pace with warming climate 2In the Eastern US, spring flowers keep pace with warming climate 3'Shell-shocked' crabs can feel pain 2Researchers attack HIV's final defenses before drug-resistant mutations emerge 2Researchers attack HIV's final defenses before drug-resistant mutations emerge 3
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Immunogen: Recombinant rabbit tryptophan hydroxylase, isolated as inclusion bodies from E. coli and purified by preparative SDS-PAGE. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... GeneBLAzer cell-based assays utilize the ... of the negatively charged fluorescent beta-lactamase ... esters readily enter the cell, where ... converts them into their negatively charged ...
Biology Products: